Iqirvo access in Bahrain: the NHRA named-patient pathway
How patients in the Kingdom of Bahrain legally obtain Iqirvo (elafibranor) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Bahrain access Iqirvo (elafibranor) for primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA, or as monotherapy in adults who are unable to tolerate UDCA through the NHRA named-patient pathway, a National Health Regulatory Authority-administered mechanism that allows a Bahraini-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BHD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Bahraini patients need Iqirvo through the named-patient pathway
The Kingdom of Bahrain operates a structured pharmaceutical regulatory environment. Iqirvo (elafibranor) is regulated through NHRA (National Health Regulatory Authority) channels, and a Bahraini family asking for Iqirvo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Iqirvo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. GIG Bahrain and Solidarity Bahrain each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bahrain or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the NHRA named-patient pathway is the mechanism that connects a Bahraini-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Iqirvo is an oral dual peroxisome-proliferator-activated receptor (PPAR) alpha and delta agonist administered once daily, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Iqirvo in Bahrain
Iqirvo (elafibranor; Ipsen / GENFIT) is an oral dual peroxisome-proliferator-activated-receptor (PPAR) alpha and delta agonist administered once daily at 80 mg. The drug received FDA accelerated approval in 2024 for adults with primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) when there is an inadequate response to UDCA, or as monotherapy when UDCA is not tolerated.
As of 2026-05-31, no public Bahrain NHRA marketing authorisation for elafibranor has been observed on the NHRA Pharmaceutical Product Regulation. Access proceeds through the NHRA Pharmaceutical Product Regulation Directorate as a personal-importation / named-patient file under Bahrain Law No. 18 of 1997.
The file specifies the PBC diagnostic criteria (anti-mitochondrial antibody positive, or AMA-negative with characteristic histology, plus elevated alkaline phosphatase), the prior UDCA adequacy assessment (typically 12 months of UDCA at 13 to 15 mg/kg/day with inadequate biochemical response by the POISE / GLOBE / UK-PBC criteria), or the UDCA-intolerance documentation, and the once-daily 80 mg elafibranor dosing plan.
The contraindication in decompensated cirrhosis (Child-Pugh class B or C) and the warning on hepatic decompensation are referenced in the file. Baseline FibroScan or biopsy-based fibrosis staging is part of the eligibility assessment.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Bahrain where Iqirvo is dispensed
Elafibranor is a hepatology / gastroenterology product. Bahraini tertiary centres with hepatology services for chronic PBC management:
- Salmaniya Medical Complex (SMC), Manama - Department of Internal Medicine, Hepatology / Gastroenterology service.
- King Hamad University Hospital, Busaiteen - Department of Internal Medicine; multi-specialty academic tertiary with hepatology consultation.
- Bahrain Defence Force Royal Medical Services Hospital (BDF Hospital), Riffa - multi-specialty tertiary with hepatology service for military families.
- Bahrain Specialist Hospital, Juffair - private tertiary multi-specialty with hepatology consultant roster.
- Royal Bahrain Hospital, Saar - private tertiary with hepatology service.
Bahrain is a small market; complex PBC cases with advanced fibrosis or treatment-refractory disease may be referred regionally to Saudi Arabia (KFSHRC Liver Centre, KFSHRC Riyadh) or UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). The NHRA file may name a Bahraini hospital with cross-border-referral arrangement.
Local pricing reference for Iqirvo in Bahrain
US WAC reference for Iqirvo (elafibranor, 80 mg oral tablets) is in the order of USD 9,500 to USD 12,000 per 30-day supply at the FDA-labelled once-daily regimen. Source: Iqirvo FDA Prescribing Information.
No public BHD reference price for elafibranor has been observed on NHRA or MOH published lists as of 2026-05-31. BHD reference at 1 BHD = USD 2.65: per-month indicative BHD reference is approximately BHD 3,600 to BHD 4,500.
Price snapshot date: 2026-05-31. Concomitant UDCA is locally available and is a separate cost line. Monitoring (LFTs, lipid panel, fibrosis-staging surveillance via FibroScan annually) is locally sourced.
Country-specific access barriers for Iqirvo in Bahrain
The first access barrier for elafibranor in Bahrain is the prior-UDCA-adequacy documentation. The FDA label requires 12 months of UDCA at adequate dose with inadequate biochemical response (or UDCA intolerance). The Bahraini hepatologist's file specifies the UDCA dosing history, the biochemical response over time (ALP, bilirubin, AST, ALT trends), and the response classification per POISE / GLOBE / UK-PBC criteria. Most Bahraini PBC patients are managed at SMC or KHUH initially on UDCA; the step-up to elafibranor or to obeticholic acid (Ocaliva, the alternative second-line option) is decided at the hepatology MDT level.
Public-sector funding posture: Bahraini nationals receive specialty drug coverage through MOH facilities at no or low cost; UDCA is formulary-listed and routine. The high-cost second-line PBC therapies (elafibranor, obeticholic acid) enter the MOH Specialty Pharmacy budget on case-by-case approval; eligibility is decided at the MOH high-cost-medicine committee level. For expatriate residents, private insurance coverage of novel PBC therapy is policy-specific.
The hepatic-decompensation safety signal in the elafibranor label is determinative. The dispensing-pharmacy clinical pathway includes baseline and serial LFTs, fibrosis-stage assessment via FibroScan or biopsy, and immediate discontinuation criteria. PBC is a chronic indication and continuous therapy is the rule; each NHRA permit covers a defined supply window (typically 3 months) with permit renewal at the recurring cycle.
The ambient-storage oral tablets simplify customs handling. Each NHRA permit covers a defined supply window; continuous-therapy patients re-apply per cycle.
Recent local regulatory news touching Iqirvo or its drug class in Bahrain
No NHRA bulletin specifically naming elafibranor or the dual-PPAR-alpha-delta-agonist class has been observed in the last twelve months on the NHRA Pharmaceutical Product Regulation page as of 2026-05-31. Adjacent context:
- FDA accelerated approval of elafibranor in 2024 is the recent regulatory event; the confirmatory study (ELATIVE) post-marketing data and the comparative-effectiveness data versus obeticholic acid and seladelpar continue to accumulate. Source: FDA Drugs@FDA database.
- The American Association for the Study of Liver Diseases (AASLD) PBC management guidance has been updated incorporating elafibranor and the broader second-line PBC therapeutic landscape; regional hepatology professional societies typically follow. Source: AASLD.
What your physician needs to provide
For a Bahraini-licensed specialist prescribing Iqirvo through the NHRA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA, or as monotherapy in adults who are unable to tolerate UDCA, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Iqirvo is the appropriate next step given an oral dual peroxisome-proliferator-activated receptor (PPAR) alpha and delta agonist administered once daily.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Iqirvo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Bahraini license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Iqirvo in Bahrain
Will GIG Bahrain and Solidarity Bahrain cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Iqirvo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by NHRA? The NHRA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; NHRA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bahraini-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The NHRA professional licensing directorate verifies the active license; the NHRA application records both the prescribing physician and the dispensing facility.
Can I receive Iqirvo at home? The dispensing facility must be Bahraini-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Iqirvo cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace NHRA, and we do not replace your dispensing pharmacy. For Iqirvo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bahrain, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Iqirvo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the NHRA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Iqirvo is a dual PPAR alpha/delta agonist for PBC with inadequate UDCA response or UDCA intolerance; named-patient files document the duration of prior UDCA, alkaline phosphatase trajectory, and baseline lipid profile (fenofibrate-class effects are well characterised). Bahrain hepatology programmes manage these cases.
Next step
If your Bahraini physician has prescribed Iqirvo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.